FLUDEOXYGLUCOSE (18F) INJECTION SOLUTION

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

FLUDEOXYGLUCOSE 18F

Fáanlegur frá:

BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY

ATC númer:

V09IX04

INN (Alþjóðlegt nafn):

FLUDEOXYGLUCOSE (18F)

Skammtar:

0.5GBQ

Lyfjaform:

SOLUTION

Samsetning:

FLUDEOXYGLUCOSE 18F 0.5GBQ

Stjórnsýsluleið:

INTRAVENOUS

Einingar í pakka:

15G/50G

Gerð lyfseðils:

Schedule C

Lækningarsvæði:

ROENTGENOGRAPHY

Vörulýsing:

Active ingredient group (AIG) number: 0152591001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2014-10-14

Vara einkenni

Fludeoxyglucose (
18
F)
1
PRODUCT MONOGRAPH
TRADE NAME
Fludeoxyglucose (
18
F) Injection
Parenteral Solution, > 0.5 GBq/ vial
Diagnostic Radiopharmaceutical
BC Cancer, part of the Provincial Health Services Authority
600 West 10th Avenue
Vancouver, BC
V5Z 4E6.
Date of Approval:
August 2, 2019
Control #: 227258
Fludeoxyglucose (
18
F)
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
DESCRIPTION
...............................................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
4
CONTRAINDICATIONS
..............................................................................................................
5
WARNINGS AND PRECAUTIONS
.............................................................................................
5
ADVERSE REACTIONS
...............................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
7
DOSAGE AND ADMINISTRATION
...........................................................................................
7
RADIATION DOSIMETRY
..........................................................................................................
9
OVERDOSAGE............................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
11
STORAGE AND STABILITY
.....................................................................................................
12
SPECIAL HANDLING INSTRUCTIONS
...............................................